Capricor Therapeutics’ (CAPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note released on Thursday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on CAPR. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. Oppenheimer restated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Maxim Group upped their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $18.61 on Thursday. Capricor Therapeutics has a fifty-two week low of $2.87 and a fifty-two week high of $23.40. The firm has a market cap of $845.08 million, a P/E ratio of -17.56 and a beta of 4.00. The business’s 50 day moving average price is $15.21 and its 200-day moving average price is $8.48.

Insiders Place Their Bets

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction on Friday, September 20th. The stock was acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in Capricor Therapeutics in the 1st quarter worth about $40,000. Main Street Financial Solutions LLC raised its holdings in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $133,000. Bank of New York Mellon Corp grew its holdings in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $161,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.